Abstract
Cytokine therapy for cancer or viral diseases is accompanied by the development of depressive symptoms in a significant proportion of patients. Despite the increasing number of studies on the neurotoxic effects of cytokines, the mechanisms by which cytokines induce depressive symptoms remain largely unknown. In view of the relationship between neurotransmitter precursors and mood, the present study aimed at assessing the relationship between serum concentrations of the amino acids tryptophan and tyrosine, major precursors of serotonin and norepinephrine respectively, and depressive symptoms in cancer patients undergoing cytokine therapy. Sixteen cancer patients eligible to receive immunotherapy with interleukin-2 and/or interferon-alpha participated in the study. At baseline and after one week and one month of therapy, depressive symptoms were assessed using the Montgomery–Asberg Depression Rating Scale (MADRS), and blood samples were collected for the determination of the large neutral amino acids (LNAA) (tryptophan, tyrosine, valine, leucine, isoleucine, phenylalanine) which compete for transport across the blood–brain barrier. Serum concentrations of tryptophan as well as the tryptophan/LNAA ratio significantly decreased between baseline, one week and one month of therapy. The development and severity of depressive symptoms, especially anorexia, pessimistic thoughts, suicidal ideation and loss of concentration were positively correlated with the magnitude of the decreases in tryptophan concentrations during treatment. These findings indicate that the development of depressive symptoms in patients undergoing cytokine therapy could be mediated by a reduced availability of the serotonin relevant amino acid precursor, tryptophan.
Similar content being viewed by others
References
Dantzer R, Wollman EE, Yirmiya R . Cytokines, Stress, and Depression Plenum, Kluwer Academic: New York 1999
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression J Affect Disord 1995 34: 301–309
Anisman H, Ravindran AV, Griffiths J, Merali Z . Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features Mol Psychiatry 1999 4: 182–188
Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells Ann Intern Med 1987 107: 293–300
Fenner MH, Hanninen EL, Kirchner HH, Poliwoda H, Atzpodien J . Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha Lancet 1993 341: 372
Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K . Depression from interferon therapy in patients with hepatitis C Am J Psychiatry 1999 156: 1120
Capuron L, Ravaud A, Dantzer R . Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy J Clin Oncol 2000 18: 2143–2151
Licinio J, Kling MA, Hauser P . Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes Sem Oncol 1998 25 (suppl 1): 30–38
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 1996 14: 7–17
Kammula US, White DE, Rosenberg SA . Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer Cancer 1998 83: 797–805
Capuron L, Ravaud A . Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state New Engl J Med 1999 340: 1370
Maes M, Meltzer HYM . The serotonin hypothesis of major depression. In: Bloom F, Kupher D (eds) Psychopharmacology: the Fourth Generation of Progress Raven Press: New York 1995 933–944
Meyers S . Use of neurotransmitter precursors for treatment of depression Altern Med Rev 2000 5: 64–71
Curzon G, Sarna GS . Tryptophan transport to the brain: new findings and older ones reconsidered. In: Schlossberger HG, Kochen W, Linzen B, Steinhart H (eds) Progress in Tryptophan and Serotonin Research Walter de Gruyter: Berlin-New York 1984 145–157
Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E . Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor Neuropsychobiology 1994 29: 108–111
DeMyer MK, Shea PA, Hendrie HC, Yoshimura NN . Plasma tryptophan and five other amino acids in depressed and normal subjects Arch Gen Psychiatry 1981 38: 642–646
Dunn AJ, Wang J, Ando T . Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress Adv Exp Med Biol 1999 461: 117–127
Song C, Merali Z, Anisman H . Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment Neuroscience 1999 88: 823–836
Linthorst AC, Flachskamm C, Holsboer F, Reul JM . Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature Endocrinology 1994 135: 520–532
Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T . Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain Eur Neuropsychopharmacol 2000 10: 129–132
Brown RR, Lee MC, Kohler PC, Hank JA, Storer BE, Sondel PM . Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2 Cancer Res 1989 49: 4941–4944
Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG . Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS Adv Exp Med Biol 1991 294: 425–435
Maes M, Meltzer HY, Scharpe S, Bosmans E, Suy E, De Meester I et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression Psychiatry Res 1993 49: 151–165
Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH . Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis J Clin Oncol 1992 10: 1119–1123
Négrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 1998 338: 1272–1278
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 1998 59 (suppl 20): 22–33
Montgomery SA, Asberg M . A new depression scale designed to be sensitive to change Br J Psychiatry 1979 134: 382–389
Turnell DC, Cooper JD . Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography Clin Chem 1982 28: 527–531
Maes M, Wauters A, Verkerk R, Demedts P, Neels H, Van Gastel A et al. Lower serum L-tryptophan availability in depression as a marker of a more generalized disorder in protein metabolism Neuropsychopharmacology 1996 15: 243–251
Smith KA, Fairburn CG, Cowen PJ . Relapse of depression after rapid depletion of tryptophan Lancet 1997 349: 915–919
Moore P, Landolt H, Seifritz E, Clark C, Bhatti T, Kelsoe J et al. Clinical and physiological consequences of rapid tryptophan depletion Neuropsychopharmacology 2000 23: 601–622
Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients Arch Gen Psychiatry 1994 51: 865–874
Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory Neuropharmacology 1994 33: 575–588
Smith KA, Morris JS, Friston KJ, Cowen PJ, Dolan RJ . Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion Br J Psychiatry 1999 174: 525–529
Neumeister A, Praschak-Rieder N, Besselmann B, Rao ML, Gluck J, Kasper S . Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy Arch Gen Psychiatry 1997 54: 133–138
Oquendo MA, Mann JJ . The biology of impulsivity and suicidality Psychiatr Clin North Am 2000 23: 11–25
Plata-Salaman CR . Cytokines and anorexia: a brief overview Semin Oncol 1998 25 (1 Suppl 1): 64–72
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans Arch Gen Psychiatry 2001 58: 445–452
Heyes MP, Saito K, Markey SP . Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid Biochem J 1992 283: 633–635
Mellor AL, Munn DH . Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999 20: 469–473
Saito K, Markey SP, Heyes MP . Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice Brain Res 1991 546: 151–154
Daubener W, MacKenzie CR . IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism Adv Exp Med Biol 1999 467: 517–524
Carlin JM, Borden EC, Sondel PM, Byrne GI . Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures J Immunol 1987 139: 2414–2418
Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M et al. Treatment with interferon-alpha (IFNalpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNalpha-induced depressive and anxiety symptoms and immune activation Mol Psychiatry 2001 6: 475–480
Fuchs D, Moller AA, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich MP et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection Immunol Lett 1991 28: 207–211
Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H . Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms J Acquir Immune Defic Syndr 1990 3: 873–876
Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa New Engl J Med 2001 344: 961–966
Acknowledgements
The authors thank the patients for participating in the study, and Simon Scharpe, PhD, Robert Verkerk, PhD, and Norbert Gualde, MD, PhD, and their colleagues for their technical assistance. Supported by Ligue Nationale contre le Cancer, Fondation pour la Recherche Medicale, and Association pour la Recherche sur le Cancer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Capuron, L., Ravaud, A., Neveu, P. et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7, 468–473 (2002). https://doi.org/10.1038/sj.mp.4000995
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4000995
- Springer Nature Limited
Keywords
This article is cited by
-
Kynurenine pathway and its role in neurologic, psychiatric, and inflammatory bowel diseases
Molecular Biology Reports (2023)
-
Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study
Psychopharmacology (2022)
-
Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease
Journal of Neuroinflammation (2021)
-
Neuromodulation by the immune system: a focus on cytokines
Nature Reviews Immunology (2021)
-
The kynurenine pathway: a finger in every pie
Molecular Psychiatry (2020)